Biomarker discovery

Protein biomarker discovery is an important field that can aid in clinical diagnosis of a range of diseases. A defective gene can be translated into an abnormal protein 

A typical biomarker discovery involves three steps (1) identification of biomarkers, (2) prioritization of markers, and (3) validation of prioritized markers. In the first step of this specific example, the cell cnltnre was treated separately by five drngs, three that can indnce idiosyncratic hepatoxicity and the remaining two nontoxic. The proteins were analyzed nsing the MUDPIT proteomics approach (see Fignre 8.12a). A set of 700 potential biomarkers were identified. In the second 

Treated, Immortalized HHA Collection of supernatants Proteolytic cells Expressing P450 3A4 Digestion 

---

BACTERIAL PROTEIN BIOMARKER DISCOVERY A FOCUSED APPROACH TO DEVELOPING MOLECULAR-BASED IDENTIFICATION SYSTEMS... 

Additionally it has been our experience that mass spectrometry as a routine detection/identification technique for bacteria is not well received by microbiologists and clinicians who prefer less expensive, less complicated approaches to bacterial typing and identification, such as methods based on polymerase chain reaction (PCR) and enzyme-linked immunosorbent assays (ELISA). For that reason we have adapted our MS approach to serve as a means of biomarker discovery that feeds candidate proteins or leads into development as PCR targets or other immunoassay techniques. 

It is therefore not surprising that the interest in PyMS as a typing tool diminished at the turn of the twenty-first century and hence why taxonomists have turned to MS-based methods that use soft ionization methods such as electrospray ionization (ESI-MS) and matrix-assisted laser desorption ionization (MALDI MS). These methods generate information-rich spectra of metabolites and proteins, and because the molecular ion is seen, the potential for biomarker discovery is being realized. The analyses of ESI-MS and MALDI-MS data will still need chemometric methods, and it is hoped that researchers in these areas can look back and learn from the many PyMS studies where machine learning was absolutely necessary to turn the complex pyrolysis MS data into knowledge of bacterial identities. 

A TWO-DIMENSIONAL LIQUID MASS MAPPING TECHNIQUE FOR BIOMARKER DISCOVERY... 

Meistermann H, Norris J, Aerni H, et al. Biomarker discovery by imaging mass spectrometry transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol. Cell. Proteomics 2006 5 1876-1886. 

The previous chapters have dealt mainly with LC/MS analysis involving short run times, many samples, and relatively small numbers of compounds in samples. What about samples containing very complex compound mixtures, for example, natural products, samples from biomarker discovery, protein digests, and QA/QC method development or metabolite identification samples requiring detection of every component Such workflows often require several analysis steps with different columns and different mobile phases and pH values to increase the separation probability by changing the selectivities of individual runs. 

Kolch, W., Neususs, C., Pelzing, M., and Mischak, H. (2005). Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 24, 959-977. 

Servais, A. C., Crommen, J., and Fillet, M. (2006). Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery. Electrophoresis 27, 2616—2629. 

Surface enhanced laser desorption/ionization (SELDI) is a distinctive form of laser desorption ionization where the target plays an active role in the sample preparation procedure and ionization process [49]. Depending on the chemical or biochemical treatment, the SELDI surface acts as solid phase extraction or an affinity probe. Chromatographic surface is used for sample fractionation and purification of biological samples prior to direct analysis by laser desorption/ ionization. SELDI is mainly applied for protein profiling and in biomarker discovery by comparing protein profiles from control and patient groups. 

Connor SC, Wu W, Sweatman BC, et al. Effects of feeding and body weight loss on the IH-NMR-based urine metabolic profiles of male Wistar Han rats implications for biomarker discovery. Biomarkers 2004 9 156-79. 

Ulrich H, Wrenger C (2009) Disease-specific biomarker discovery by aptamers. Cytometry A... 

A final caveat in the RPAIA field that limits biomarker discovery as well as other uses in drug development is the somewhat limited panel of antibodies that have been validated to date for the platform. Many antibodies that work on western blots have the potential to work with RPMAs as well, because in both platforms proteins are in a denatured state. However, because the molecular weight of analytes detected by RPMA cannot be known, it is imperative to demonstrate the specificity of antibodies, usually measured by the absence of nonspecific reactive bands on western blots developed under similar blocking conditions. A second requirement for antibody validation is proof of principle that an antibody detects quantitative changes in the expected target on an... 

Rifai, N., Gillette, M. and Carr, S.A. (2006) Protein biomarker discovery and validation the long and rmcertain path to clinical utility. Nature Biotechnology, 24 (8), 971-983. 

Metabolomics analysis with the devTOX platform was performed in collaboration with Stemina Biomarker Discovery, Inc. 

Gronborg, M., Kristiansen, T.Z., Iwahori, A., Chang, R., Reddy, R, Sato, N., Molina, H., Jensen, O.N., Hruban, R.H., Coggins, M.G., et al, (2006) Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach. Mol Cell Proteomics, 5, 157-171. 

---